Business
Study: Parsortix use in metastatic breast cancer
Study: Parsortix use in metastatic breast cancer.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n RNS Number : 4029T\n Angle PLC\n 20 July 2020\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 20 July 2020\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n RESEARCH STUDY INVESTIGATES USE OF PARSORTIX LIQUID BIOPSY FOR METASTATIC BREAST CANCER PATIENTS \n \n \n \n \n \n Pilot study compared Parsortix liquid biopsy to tissue biopsy of a metastatic site\n \n \n \n \n \n Potential actionable therapeutic targets were found in the Parsortix liquid biopsy that were missed in the tissue biopsy of a single metastatic site \n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC) highlighting key advantages of a Parsortix liquid biopsy compared to standard of care tissue biopsy. In addition to the known advantages of a non-invasive, repeatable, low cost procedure, USC showed that potential actionable therapeutic targets were found in the Parsortix liquid biopsy that were missed in the tissue biopsy of a single metastatic site. \n \n \n \n \n \n The research investigated concordance between cancer cells obtained from the blood test (CTCs harvested by Parsortix) and cancer cells obtained from the metastatic tissue biopsy across 4,600 medically relevant genes and demonstrated that the use of single-site metastatic tumour biopsy, which is standard of care under the NCCN US national cancer guidelines, is unlikely to provide complete insight into tumour mutational status. Tissue biopsy is also limited by the quality, quantity and availability of tumour tissue. The study concluded that medically significant mutations may be found in the CTCs that are not expressed in the metastatic tissue biopsy. 51 actionable genes were identified in the CTCs including the 39 most frequently mutated genes in metastatic breast cancer. \n \n \n \n \n \n This study demonstrates key capabilities of Parsortix for metastatic breast cancer, which is the area of focus for ANGLE's FDA submission currently in preparation with the aim of submission later this quarter (Q3 CY20). \n \n \n \n \n \n The research has been published as a peer-reviewe...